ALKS — Alkermes plc

Is ALKS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Neutral As of August 19, 2026

Alkermes plc (ALKS) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $50.18. The rating moved from Oversold to Neutral on August 19, 2026.

AI analysis

Alkermes plc (ALKS) presents a mixed near-term profile: recurring revenue from specialty CNS/addiction products and an IP position in long‑acting formulations provide a base of cash flow and optionality from pipeline programs. The company sits in a sector with active biologics/advanced therapy interest and elevated M&A multiples, which could enable partnership or strategic outcomes. However, clinical, regulatory, reimbursement, and financing risks remain material and could drive volatility. With market sentiment currently balanced and no major macro catalysts, the stock appears fairly valued in the short run with modest upside tied to positive clinical or deal news and downside protection from steady commercial revenues.

Key factors

  • Alkermes plc (ALKS) has an established commercial footprint in specialty CNS and addiction therapies which supports near-term revenue visibility relative to pre-commercial peers.
  • Pipeline of long-acting injectable and formulation technologies that, if successful, can extend product life cycles and create differentiated clinical positioning.
  • Sector thematic tailwinds for advanced biologics and specialty therapeutics could support partnership or licensing interest, providing non-dilutive funding or milestone upside.
  • Current market tone is balanced with selective interest in growth names; no major macro or geopolitical shocks in the short window reduces headline risk.
  • Relative defensiveness in healthcare sector rotation may support downside protection versus broader growth names in the near term.
  • Potential for strategic transactions (asset sales, collaborations) given elevated M&A multiples in biotech/pharma, which could re-rate the equity if executed favorably.

Risks

  • Clinical trial setbacks or regulatory delays for pipeline programs could materially impact valuation and near-term investor sentiment.
  • Reimbursement and payer pressure for specialty therapies can limit commercial uptake and pricing power, especially in addiction and CNS categories.
  • Competition from larger pharma players and new modality entrants (including GLP-1-related or alternative CNS approaches) could erode market share.
  • Need for additional capital or partner funding could result in dilution if internal cash generation and financing options are constrained.
  • Execution risk around manufacturing scale-up, device/formulation commercialization, or supply-chain disruptions.
  • Adverse regulatory or litigation outcomes (product liability, labeling disputes) could create financial and reputational headwinds.
  • Limited near-term social sentiment or retail interest may make the stock more sensitive to news flow and institutional trading patterns.
  • Macroeconomic shifts or a reversal in risk appetite for biotech stocks could compress multiples and depress the equity irrespective of fundamentals.

See today's live rating, score and targets

Members see the live hourly rating for ALKS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.